Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) was upgraded by equities researchers at BTIG Research to a "strong-buy" rating in a research report issued on Thursday, MarketBeat.com reports. The brokerage currently has a $44.00 target price on the stock. BTIG Research's target price suggests a potential upside of 293.21% from the company's current price.
ORKA has been the subject of a number of other reports. Wedbush reaffirmed an "outperform" rating and issued a $40.00 target price on shares of Oruka Therapeutics in a report on Thursday, May 15th. Wolfe Research assumed coverage on Oruka Therapeutics in a report on Tuesday, February 4th. They set an "outperform" rating and a $20.00 price objective for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $45.00 target price on shares of Oruka Therapeutics in a report on Friday, February 7th. One investment analyst has rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $40.38.
Read Our Latest Research Report on Oruka Therapeutics
Oruka Therapeutics Trading Up 5.8%
Shares of ORKA opened at $11.19 on Thursday. The stock's 50 day moving average is $9.80 and its two-hundred day moving average is $14.40. Oruka Therapeutics has a twelve month low of $5.49 and a twelve month high of $31.13. The firm has a market capitalization of $418.96 million, a PE ratio of -1.79 and a beta of 0.25.
Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.17. On average, sell-side analysts predict that Oruka Therapeutics will post -3.41 EPS for the current year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the business. China Universal Asset Management Co. Ltd. purchased a new stake in Oruka Therapeutics in the fourth quarter valued at approximately $144,000. AlphaCentric Advisors LLC acquired a new stake in Oruka Therapeutics in the 4th quarter valued at $119,000. Charles Schwab Investment Management Inc. acquired a new stake in Oruka Therapeutics in the 4th quarter valued at $303,000. Vanguard Group Inc. raised its position in Oruka Therapeutics by 4,161.2% in the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company's stock valued at $31,231,000 after purchasing an additional 1,572,853 shares during the period. Finally, JPMorgan Chase & Co. acquired a new position in shares of Oruka Therapeutics during the fourth quarter worth about $54,000. Hedge funds and other institutional investors own 56.44% of the company's stock.
About Oruka Therapeutics
(
Get Free Report)
Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Featured Articles
Before you consider Oruka Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oruka Therapeutics wasn't on the list.
While Oruka Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
